BRAF and melanoma: Our work shows that mutated BRAF melanoma patients with high levels of ZEB1 expression may not benefit from MAPKi treatment and that ZEB1 could serve as a predictive marker in order to stratify BRAF‐mutated melanoma into MAPKi‐sensitive and MAPKi‐resistant subgroups.